Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen Sells 3,331 Shares of Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen sold 3,331 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $7.00, for a total value of $23,317.00. Following the sale, the chief executive officer now directly owns 74,123 shares in the company, valued at approximately $518,861. The trade was a 4.30 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Atara Biotherapeutics Trading Up 2.5 %

ATRA stock opened at $7.31 on Thursday. The company has a market capitalization of $42.11 million, a PE ratio of -0.28 and a beta of 0.46. Atara Biotherapeutics, Inc. has a 12-month low of $5.40 and a 12-month high of $20.81. The business’s fifty day moving average price is $10.09 and its 200 day moving average price is $9.75.

Institutional Investors Weigh In On Atara Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of ATRA. Marshall Wace LLP purchased a new stake in shares of Atara Biotherapeutics in the 4th quarter valued at $332,000. Birchview Capital LP purchased a new stake in Atara Biotherapeutics during the 4th quarter worth about $293,000. Cubist Systematic Strategies LLC purchased a new stake in Atara Biotherapeutics during the 4th quarter worth about $169,000. Vestal Point Capital LP increased its holdings in Atara Biotherapeutics by 11.3% during the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after purchasing an additional 12,677 shares during the period. Finally, Northern Trust Corp purchased a new stake in Atara Biotherapeutics during the 4th quarter worth about $149,000. Hedge funds and other institutional investors own 70.90% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on ATRA. RODMAN&RENSHAW downgraded Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 21st. HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a research report on Tuesday, January 28th. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, November 29th. Canaccord Genuity Group cut their price objective on Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, January 17th. Finally, Rodman & Renshaw started coverage on Atara Biotherapeutics in a research report on Friday, December 20th. They set a “buy” rating and a $25.00 price target for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $17.75.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.